With the transcriptional inhibitor actinomycin D treatment, the half‐life of ALKBH3 mRNA in HCC cells with ALKBH3‐AS1 knockdown was shorter than in control cells (Figure 4F). This evidence concerns the gene ALKBH3 and hepatocellular carcinoma.